Non-invasive Liver Screening Using FibroScan Device for Liver Disease Patients for the Steatosis/Fibrosis Database

State University of New York at Buffalo1,000 enrolled

Overview

The primary goal of this study is to establish a database of people with varying levels of hepatic fibrosis and various etiologies of liver disease for use in future research protocols.

The Fibroscan device will determine liver stiffness as well as the amount of fat through another application on the machine called controlled attenuation parameter or Controlled Attenuation Parameters (CAP). The liver stiffness measurements are then translated into a score that tells how much liver fibrosis or fat is present. Patients identified with potential for fatty liver or specific liver-related diseases causing fibrosis would be approached for a voluntary FibroScan measurement. From these patients, the investigators will collect information related to demographics, disease history, medical comorbidities, social history, laboratory and radiologic parameters. This information, along with clinical data associated with the patient will be placed in a database for use in identifying potential subjects for future trials.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Disease of Liver and Bile Duct

Interventions

vibration controlled transient elastography (VCTE)PROCEDURE

Once on the examination table, the subject will be instructed to place the right arm under their head and to cross their right ankle over the left ankle. The subject will then be asked to slightly bend to the left side to open the intercostal space. Subsequently, a handheld probe is placed in the intercostal space overlaying the right hepatic lobe. The velocity of returning shear waves, measured at a depth of 25-65 mm, is converted into a liver stiffness measurement (LSM). The LSM obtained from a given VCTE exam is the median value of at least 10 successful measurements. This information, along with clinical data associated with the patient will be placed in a database for use in identifying potential subjects for future trials.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with known, or suspected risk factors for steatosis (fat) or hepatic fibrosis * Subjects who have been previously diagnosed with Non-Alcoholic Steatohepatitis (NASH) but who do not have current steatosis (fat) or fibrosis scoring * Subjects who have other known liver diseases ie: HCV Exclusion Criteria: * Patients less than 18 years of age * Pregnancy * Patients that do not want to be contacted for consideration in future research studies. * Patients diagnosed with ascites or peritoneal dialysis * Body mass index (BMI) ≥40

Locations (1)

Conventus Medical Office Building

Buffalo, New York, United States

RECRUITING

Outcomes

Primary Outcomes

measurement of fibrosis in patients with varying degrees of liver disease

single event per patient with liver disease to measure degree of fibrosis concentration

Time frame: 10 years

Secondary Outcomes

measurement of liver fat in patients with varying degrees of liver disease

single event per patient with liver disease to measure degree of fat concentration

Time frame: 10 years

Central Contacts

Ajay Chaudhuri, MD

CONTACT

716-907-1916 achaudhu@buffalo.edu

Andrew Talal, MD

CONTACT

716-888-4737 ahtalal@buffalo.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.